Chronic chilblains
Conditions
Interventions
The intervention which is compared to the placebo consists of the oral
administration 30mg nifedipine with regulated release once a day for two weeks
and twice a day for four weeks.
Sponsors
Huisartspraktijk Souwer
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 18 years or older; able to understand and follow instructions; Complaints of chronic pernio for at least 3 weeks at inclusion: itching or painful blue-red discolorated lesions at fingers and/or toes, other localisations at the feet or lateral side of the thighs ("the Kibes"). The lesions may be swollen and ulceration may be present but is not obligitory. Onset of complaints is in the period November to Februari.
Exclusion criteria
Exclusion criteria: Known inflamatory disease (RA, SLE etcetera); pregnancy; lactation; Use of Nifidipine or another calcium antagonis; hypotension (bloodpressure lower than 110/60, angina pectoris, recent myocardial infection (less than 1 month), heart failure, known liver or kidney failure, severe gastro-intentinal stricturation; use of rifampicine, fenytoin, cimetidine or ranitidine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We consider the intervention effective if a reduction of the experienced complaints is found, displayed in a decline of the score "complaint" with at least 10 mm on the visual analogue scale concerned. "Complaint" is defined as Max (itch,pain): the Vas score for or itch or pain, depending on the highest score. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary we register scores for impairment and the experienced side effects: headache and dizziness. | — |
Countries
Netherlands
Outcome results
None listed